The dual aims of this therapy are to prevent adrenal insufficiency and suppress androgen excess through direct negative feedback on pituitary adrenocorticotropic hormone (ACTH) secretion, while minimizing GC-induced iatrogenic cushingoid features like osteoporosis and a worse cardio-metabolic profile [3]. The gene discussed is POMC; the disease is Adrenal insufficiency.